Weightwatchers and bariatric surgery had limited effects on the obese brain, but GLP-1s like Ozempic may mean new hope in ...

Estrogen generated in the brain may play a role in regulating appetite, potentially opening new avenues for treating obesity.

I worry about how these changes, which are occurring at the age of 13 or 14, might affect them later in life,” the study’s ...

While the US leads in early-phase obesity trials and investment, the country also faces challenges in disease burden, trial ...

Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down following a plunge in the company's share price ...

Novo Nordisk A/S’s surprise decision to replace Chief Executive Officer Lars Fruergaard Jorgensen has triggered a race to ...

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

A survey of adults living with obesity and their physicians across seven countries reveals a high disconnect between their ...

However, many on Wall Street believe that better days lie ahead for Novo Nordisk. Analysts expect this obesity drug stock to ...

Queen Latifah opens up about obesity and heart health risks for public awareness campaign, Truth About Weight.

A digital obesity clinic, Embla, is associated with 16.7% weight loss over 64 weeks, matching previous semaglutide trial ...

The $7.8 million investment will fund further drug testing and development to advance its drug candidates to clinical trials.